Showing results (1751-1760 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|April 3, 2018
Autophagy inhibition improves the chemotherapeutic efficacy of cruciferous vegetable-derived diindolymethane in a murine prostate cancer xenograft modelHossam Draz, Alexander A Goldberg, Emma S Tomlinson Guns, et al.
Investigational New Drugs|April 3, 2018
New NO- and H2S-releasing doxorubicins as targeted therapy against chemoresistance in castration-resistant prostate cancer: in vitro and in vivo evaluationsElisabetta Bigagli, Cristina Luceri, Maria De Angioletti, et al.
Investigational New Drugs|June 28, 2018
Phase II study of DFP-10917, a deoxycytidine analog, given by 14-day continuous intravenous infusion for chemotherapy-refractory advanced colorectal cancerAmir Mehrvarz Sarshekeh, Henry Q Xiong, Kenzo Iizuka, et al.
Investigational New Drugs|June 23, 2018
Alteration of benzo(a)pyrene biotransformation by resveratrol in ApcMin/+ mouse model of colon carcinogenesisAshley C Huderson, P V Rekha Devi, Mohammad S Niaz, et al.
Investigational New Drugs|June 30, 2017
Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing observational studyJunichiro Watanabe, Yoshinori Ito, Shozo Ohsumi, et al.
Investigational New Drugs|February 21, 2015
Phase I and pharmacokinetic study of the novel anthracycline derivative 5-imino-13-deoxydoxorubicin (GPX-150) in patients with advanced solid tumorsSarah A Holstein, James C Bigelow, Richard D Olson, et al.
Investigational New Drugs|February 25, 2015
A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumorsJohanna C Bendell, Carla Kurkjian, Jeffrey R Infante, et al.
Investigational New Drugs|January 29, 2014
An assessment of the pharmacokinetics, pharmacodynamics, and tolerability of GCPGC, a novel pegylated granulocyte colony-stimulating factor (G-CSF), in healthy subjectsKwang-Hee Shin, Kyoung Soo Lim, Howard Lee, et al.
Investigational New Drugs|February 3, 2015
Phase 1b study of the oral gemcitabine 'Pro-drug' LY2334737 in combination with capecitabine in patients with advanced solid tumorsJeffrey R Infante, Karim A Benhadji, Grace K Dy, et al.
Investigational New Drugs|May 17, 2014
The novel kinase inhibitor EMD1214063 is effective against neuroblastomaKathy Scorsone, Linna Zhang, Sarah E Woodfield, et al.
Pageof 372